Avego BioScience Capital
Venture capitalActively deployingAlpharetta Β· Series AβLate Stage
Also known as AVEGO MANAGEMENT, LLC
Investment thesis
Avego invests across the healthcare continuum in private and public companies commercializing innovative products for patients and practitioners, using a multi-stage approach informed by the team's scientific and operating backgrounds. Its distinct strategies include Avego Healthcare Capital (growth capital to revenue-generating businesses and company building), Avego BioScience Capital (mid-to-late stage biotech venture financings), and Velan Capital (public healthcare equities with a focus on undervalued assets). The firm emphasizes evidence-based scientific diligence, financial alignment through investing its own capital, hands-on operating support, talent recruitment, and corporate development, aiming to accelerate growth and improve patient outcomes.
Source: firm website, verified Aug 3, 2026.
What they invest in
from 10 of 41 portfolio companiesBiotech Γ10Medical Devices Γ2
HQs:United StatesΓ9
Investments Β· 41 tracked
founders shown can be your intro pathCaribou Biosciences is a clinical-stage biopharmaceutical company developing CRISPR genome-editing therapies, including off-the-shelf CAR-T cell therapies for hematologic malignancies and armored cell therapies using its Cas12a chRDNA platform.
BiotechMedical DevicesBerkeley, US
Jennifer Doudna(Co-founder)Rachel Haurwitz(President and Chief Executive Officer, Co-founder)Martin Jinek(Co-founder)Andrew May(Executive Officer)Rodolphe Barrangou(Director)Jenny Rooke(Director)
Palo Alto, US
Janice Drew(Executive Officer)David Cohen(Director)Robert Hopfner(Director)Derek DiRocco(Director)Gregory Moss(Executive Officer)Eugene Bauer(Executive Officer, Director)
BiotechAbingdon, Oxfordshire
Brian Di Donato(Chief Financial Officer)John Bell(Chairman of the Board of Directors)Robert Perez(Director)David Berman(Head of Research and Development)Tina St. Leger(Chief Human Resources Officer)Peter Ratcliffe(Director)
Biotech focused on hematopoietic cell transplant therapies.
BiotechRedwood City, US
Herb Cross(Executive Officer)Jeet Mahal(Executive Officer, Director)Patrick Crutcher(Director)Thomas Wiggans(Director)Judith Shizuru(Director)Svetlana Lucas(Director)
Biotech company developing therapies (Series D-stage).
Clinical-stage biotech developing treatments for Claudin-1 positive tumors and organ fibrosis.
Global pharmaceutical company focused on retinal health.
BiotechMendham, US
Abel De La Rosa(Director)Iyona Rajkomar(Director)Douglas Mayers(Executive Officer)Benjamin Rovinski(Director)Patrick Higgins(Director)Tamra Adams(Executive Officer)
BiotechPhiladelphia, US
Susan B Dillon(Executive Officer, Director)Karyn O'Neil(Executive Officer, Director)Mark V. Laurenzi(Executive Officer)Elizabeth Anderson(Director)Bruce Peacock(Director)
Global CDMO for GMP manufacturing and distribution of radiopharmaceuticals.
Leading independent diagnostic provider for veterinarians in the United States.
Epibiologics develops protein degradation medicines using protein sciences and antibody engineering capabilities.
BiotechMedical Devices
BoardMichael Kavanaugh(Founding Advisor)
BiotechSan Diego, US
JeenJoo Kang(Director)Robert Tjian(Director)Alain Baron(Executive Officer, Director)Marcus Boehm(Executive Officer)Andrew Schwab(Director)
US ophthalmic pharmaceutical company.
Privately-held biotech company developing biologic therapies for retinal diseases
BiotechBoston, US
Zach Scheiner(Director)William Daley Bonificio(Executive Officer, Promoter)Megan Krench(Director)Stephen Basil Thomas(Executive Officer, Promoter)Dmitrij Hristodorov(Director)Naveen Manu Daryani(Executive Officer, Director, Promoter)
BiotechCamarillo, US
Brian Lee(Executive Officer, Director)Matt Croughan(Executive Officer)Nelson Bermudez(Executive Officer)Terrell Mathews(Executive Officer)Bryan Poltilove(Director)Jung Lim(Director)
BiotechLexington, US
Cameron Wheeler(Director)Jonathan Root(Director)Laurence Lasky(Director)Victoria M. Richon(Executive Officer, Director)
Private specialty pharmaceutical company.
Biotech decoding human tissue immune biology to create therapeutics.
Frequently asked questions
- What stage does Avego BioScience Capital invest at?
- Avego BioScience Capital invests at the Series A, Series B, Series C, Growth, Late Stage stages.
- What sectors does Avego BioScience Capital focus on?
- Avego BioScience Capital focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Avego BioScience Capital located?
- Avego BioScience Capital is headquartered in Alpharetta, US.
- Does Avego BioScience Capital lead rounds?
- Yes, Avego BioScience Capital leads investment rounds.
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests from seed to growth stages across artificial intelligence, health, and sustainability-focused technologies.
Capricorn Venture Partners is a European investment firm managing several thematic funds across growth capital, healthcare, and cleantech, as well as a combined private/quoted investment vehicle.
The Novartis Venture Fund invests in innovative life science companies, focusing on biotechnology and biopharmaceuticals at various stages of growth, aiming to drive patient benefit and generate returns.
Pontifax is an investment firm focused on life sciences and healthcare technologies, backing companies across all development stages from early research to clinical-stage growth.
EQT Life Sciences, formerly LSP, is one of Europe's largest and most experienced life sciences investors, backing companies developing therapeutics, medical devices, diagnostics and healthtech globally. It is part of EQT Group.